Gust 20image
Vaporox slack icon

Vaporox

Vaporous Hyperoxia Therapy (VHT™)

  • Stage Prototype Ready
  • Industry Medical Devices and Equipment
  • Location Denver, CO, USA
  • Currency USD
  • Founded September 2016
  • Employees 10
  • Incorporation Type C-corp
  • Website vaporox.com

Company Summary

Vaporox, Inc.’s Vaporous Hyperoxia Therapy (VHT™), a patented, and FDA-510K-cleared technology, offers a breakthrough in treating 9 different types of skin wounds, including diabetic foot ulcers (DFUs).

Clinical trial data has shown that VHT can heal 80% or more of DFUs that have previously resisted standard wound care treatment, and at a much lower cost than less effective methods.

Team

  • Alan sage linkedin
    Chief Executive Officer

    Alan is a Colorado native who has been an entrepreneur since college. He has founded multiple companies. His biggest “exit” was a software company, Configuresoft, which he co-founded with two of Vaporox’s BOD members, Louis Woodhill and Alex Goldstein.

  • Default avatar
    Loren Hutchins
    Chief Product Officer

    Loren has worked in machine design and automated equipment development since 1994 and has specialized in medical devices for the past two decades. He was the lead product specialist at Baxa Corporation, which was acquired by Baxter International.

  • Valley 20floor 20headshot 2
    Chief Financial Officer

    Bryan comes to Vaporox from Telluride Medical Partners where he was a Partner and served as Chief Financial Officer of multiple portfolio companies. Previously, he worked at a multi-national investment banking firm, Credit Suisse.